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Flp-InTM T-RExTM 293 cells expressing a wild 
type human M3 muscarinic acetylcholine 
receptor construct constitutively and able to 
express a Receptor Activated Solely by 
Synthetic Ligand (RASSL) form of this 
receptor on demand maintained response to 
the muscarinic agonist carbachol but 
developed response to clozapine-N-oxide only 
upon induction of the RASSL. The two 
constructs co-localized at the plasma 
membrane and generated strong ratiometric 
fluorescence resonance energy transfer 
(FRET) signals consistent with direct physical 
interactions. Increasing levels of induction of 
the FRET-donor RASSL did not alter wild 
type receptor FRET-acceptor levels 
substantially.  However, ratiometric FRET 
was modulated in a bell-shaped fashion with 
maximal levels of the donor resulting in 
decreased FRET. Carbachol, but not the 
antagonist atropine, significantly reduced the 
FRET signal. Cell surface homogenous time-
resolved FRET, based on SNAP-tag 
technology and employing wild type and 
RASSL forms of the human M3 receptor 
expressed stably in Flp-InTM TRExTM 293 
cells, also identified cell surface 
dimeric/oligomeric complexes. Now, however, 
signals were enhanced by appropriate 
selective agonists. At the wild type receptor 
large increases in FRET signal to carbachol 
and acetylcholine were concentration-
dependent with EC50 values consistent with 
the relative affinities of the two ligands. These 
studies confirm the capacity of the human M3 
muscarinic acetylcholine receptor to exist as 
dimeric/oligomeric complexes at the surface of 
cells and demonstrate that the organization of 
such complexes can be modified by ligand 
binding. However, conclusions as to the effect 
of ligands on such complexes may depend on 
the approach used. 
 
Monomeric G protein-coupled receptors 
(GPCRs) have the capacity to bind and activate 
G proteins (1-3). Despite this, GPCRs also have 
the capacity to exist as dimers and/or oligomers 
in living cells (4-7). Such quaternary 
organization has been suggested, amongst other 
functions, to play a key role in effective folding 
and cell surface trafficking of GPCRs (8-10). 
However, a series of key questions related to 
GPCR quaternary structure remain to be 
explored fully. These include the proportion of a 
GPCR that is dimeric/oligomeric at steady-state, 
how this may be affected by receptor expression 
level, if this is regulated at different stages in the 
lifecycle of a GPCR and the ability of receptor 
ligands to alter GPCR-GPCR interactions.  
Five individual muscarinic GPCRs 
respond to the neurotransmitter acetylcholine 
(11, 12). Despite overlapping tissue distribution 
and very limited selective ligand pharmacology, 
studies on mouse lines that have selective knock-
out of individual muscarinic receptor genes 
means that a good deal is known about the roles 
of the individual subtypes (12). For example, the 
M3 receptor mediates a wide variety of 
functions, including vasodilation, 
bronchoconstriction, stimulation of pancreatic 
insulin and glucagon release, modulation of 
salivary gland function and smooth muscle 
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lation of the RASSL variant. 
contraction.  An alternative means to study the 
function of individual muscarinic receptor 
subtypes is based on the generation of receptor 
mutants that are often designated Receptors 
Activated Solely by Synthetic Ligand (RASSLs) 
(13, 14). The introduced mutation(s) result in 
loss of affinity for the endogenous ligand but 
enhanced affinity for one or more small synthetic 
ligands that have little affinity/potency at the 
wild type receptor (15, 16). In the case of 
muscarinic receptors, introduction of mutations 
at conserved amino acids in transmembrane 
domains III and V greatly alters the agonist 
potency ratio between acetylcholine and the 
synthetic ligand clozapine-N-oxide (17, 18). 
Expression of such a modified receptor, in either 
cell lines or in animals via transgenesis, can 
allow selective activation and analysis of the 
function and regu
The quaternary structure of muscarinic 
receptor family members has been explored 
extensively (19-24).  However, whether ligand 
binding regulates such interactions is an area of 
considerable controversy. Using 
bioluminescence resonance energy transfer 
(BRET)-based approaches, Goin and Nathanson 
(21) did not observe short-term agonist 
regulation of either homo- or hetero-interactions 
involving M1, M2 or M3 receptors. By contrast, 
Ilien et al., (25) have reported that the selective 
M1 receptor antagonist pirenzepine  enhances 
M1 receptor dimerization; from a situation where 
M1 receptor monomers predominate in the 
absence of ligand but dimerize upon pirenzepine 
binding. This is of particular interest because 
Hern et al., (26) have recently employed 
modified forms of the antagonist ligand 
telenzepine in single molecule tracking studies in 
CHO cells expressing the M1 receptor. These 
studies concluded that, any given time, ~30% of 
the receptor molecules exist as dimers and that 
this is a dynamic process with the M1 receptor 
undergoing inter-conversion between monomers 
and dimers within seconds. However, if 
antagonist ligand binding inherently alters such 
receptor-receptor interactions, then data 
interpretation may be difficult in studies that rely 
on imaging of a bound ligand.  GPCR quaternary 
structure has been explored by a number of 
approaches, but in recent times, these have been 
dominated by combinations of intact cell BRET 
and fluorescence-resonance energy transfer 
(FRET). These techniques are based upon energy 
transfer between either two auto-fluorescent 
proteins (in FRET studies) or an auto-fluorescent 
protein and an enzyme able to generate 
bioluminescence (in BRET studies). These 
probes are usually attached to the intracellular C-
terminal tail of GPCRs of interest (27-30). Very 
recently, a novel, homogenous time-resolved 
(htr)FRET approach has been developed. This 
takes advantage of the capacity of small proteins 
based on mammalian O6-alkylguanine-DNA-
alkyltransferase to be covalently modified with 
fluorescent and other small molecule labels (31). 
Such ‘SNAP’ tagging can allow detection of cell 
surface, as well as intracellular, protein-protein 
interactions.  As a proof of concept, this has been 
used to explore aspects of GPCR quaternary 
structure, with particular focus on members of 
the class C, metabotropic glutamate receptor 
family (32). Herein, we use combinations of dual 
color FRET imaging and ‘SNAP’ tag-based 
htrFRET of both wild type and RASSL forms of 
the human M3 muscarinic receptor to explore the 
quaternary structure of this receptor and it’s 
potential regulation by ligands.  
 
Experimental Procedures 
 
Materials – Materials for cell culture were from 
Sigma-Aldrich (Gillingham, Dorset, UK) or 
Invitrogen (Paisley, Strathclyde, UK). 
Clozapine-N-oxide was from Biomol 
International (Exeter, Devon, UK). Other drugs 
used in this study were from Sigma-Aldrich. 
Antibodies recognizing the different epitope tags 
were obtained as listed: anti-c-myc antibody 
(Cell Signalling, Hitchin, Hertfordshire, UK), 
anti-SNAP antibody (ThermoFisher Scientific, 
Epsom, Surrey, UK), monoclonal anti-Flag M2-
Peroxidase and anti-Flag M2 monoclonal 
antibodies were from Sigma-Aldrich.  The 
antiserum directed against VSV-G epitope was 
produced in-house. All secondary IgG 
horseradish peroxidise-linked antibodies were 
from GE Healthcare (Amersham, 
Buckinghamshire, UK).  The radioligand 
[ H]QNB was from Perkin Elmer 3 (Boston, MA). 
All oligonucleotides were purchased from 
ThermoElectron (Ulm, Germany). Flp-InTM T-
RExTM 293 cells were from Invitrogen (Paisley, 
Strathclyde, UK). 
 
Molecular constructs  
Generation of the hM3RASSL by site-directed 
mutagenesis 
cDNA corresponding to the human M3 
muscarinic acetylcholine receptor (hM3) 
(Accession # AF498917) was obtained from the 
Missouri S&T cDNA Resource Center 
(www.cdna.org). This was used as a template to 
generate the mutated RASSL receptor by 
substitution of the tyrosine at position 149 with a 
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cysteine (Tyr149Cys), and the alanine in position 
239 with a glycine (Ala239Gly) as described by 
Armbruster et al., (17). These mutations were 
introduced by two sequential rounds of  
mutagenesis according to the QuickChange II 
(Stratagene, La Jolla, CA) method using the 
following primers: Tyr149Cys mutation, 5' 
GCTTGCCATTGACTGCGTAGCCAGCAATG 
3' (forward), 5' 
CATTGCTGGCTACGCAGTCAATGGCAAGC 
3' (reverse); Ala239Gly mutation, 5' 
GCACAGCCATCGCTGGTTTTTATATGCCT
G 3' (forward), 5' 
CAGGCATATAAAAACCAGCGATGGCTGT
GC 3' (reverse). A least 8 clones were screened 
by DNA sequencing and positives selected and 
used for further studies. 
 
Flag-hM3WT-Citrine and myc-hM3RASSL-
Cerulean cDNA constructs 
Flag-hM3WT-Citrine and myc-hM3RASSL-
Cerulean constructs were engineered by the 
introduction by PCR of Flag or c-myc as N-
terminal epitopes. This was followed by 
subsequent in-frame ligation of the resulting 
PCR fragments into the EcoRI site of pcDNA3 
(Invitrogen) vectors harboring Citrine- or 
Cerulean-fluorescent proteins respectively. Both 
Flag-hM3WT-Citrine and myc-hM3RASSL-
Cerulean fragments were also ligated into 
pcDNA5/FRT/TO (Invitrogen) to generate stable 
inducible Flp-InTM T-RExTM 293 cell lines. In 
both cases the stop codon of the receptor was 
removed to allow transcription of the fusion 
protein. The full lengths of the fusion constructs 
were confirmed to be correct by nucleotide 
sequencing. 
 
VSV-G-SNAP-hM3WT and VSV-G-SNAP-
hM3RASSL cDNA constructs 
The plasmid pSEMS1-26m (SNAP tag) as 
supplied by Covalys Biosciences AG/New 
England Biolabs (Hitchin, UK), was modified by 
the addition of a small linker region encoding the 
metabotropic glutamate 5 receptor (mGluR5) 
signal sequence and an epitope tag (VSV-G) 
between the Cla1 and EcoR1 sites of the multiple 
cloning site upstream of the SNAP tag (MCS1). 
The linker was made by annealing two 
complementary primers containing the sequences 
described above with the addition of a Kozak 
sequence, start codon and appropriate 
nucleotides to generate Cla1 and EcoRI ‘sticky’ 
ends. The primers were annealed by combining 
1ng of each with 1x ‘multicore’ buffer (Promega 
Corporation) in a final volume of 50µl. This was 
then heated to 100˚C in a boiling water bath for 5 
minutes, after which the bath was then turned off 
and allowed to cool overnight. The annealed 
fragment was then purified by gel extraction and 
ligated into the plasmid by standard techniques. 
The receptor sequences were PCR amplified 
using primers designed to add BamHI (5’ 
CGCGGATCC GCCACC ATG 
ACCTTGCACAATAACAGT 3’) and NotI 
(5’TTTTCCTTTTGCGGCCGCCTA 
CAAGGCCTGCTCGGGTGC 3’) sites to the 
fragment termini. These were then ligated into 
the multiple cloning site downstream of SNAP 
tags (MCS2) of the modified plasmids described 
above. In order to create constructs which could 
be used to make Flp-InTM T-RExTM 293 inducible 
stable cell lines of these constructs, the entire 
insert from the Cla1 site to the Not1 site was cut 
out and ligated into a modified version of 
pcDNA5/FRT/TO (Invitrogen) with a ClaI site 
added to the multiple cloning site using a linker 
formed from two annealed primers as described 
previously.  
 
Generation of stable Flp-InTM T-RExTM 293 
cells 
Cells were maintained in Dulbecco’s 
modification of Eagle’s medium without sodium 
pyruvate, 4500 mg/liter glucose, and L-
glutamine, supplemented with 10% (v/v) fetal 
calf serum, 1% penicillin/streptomycin mixture, 
and 10 g/ml blasticidin in a humidified 
atmosphere. To generate Flp-InTM T-RExTM 293 
cells able to inducibly express the different 
cDNA constructs, cells were transfected with a 
1:9  mixture of cDNA in pcDNA5/FRT/TO 
vector and the pOG44  vector (Invitrogen) using 
Effectene (Qiagen, West Sussex, UK), according 
to the manufacturer’s instructions and as 
described previously (33-35). After 48 h, the 
medium was changed to medium supplemented 
with 200 g/ml hygromycin B (Roche) to initiate 
selection of stably transfected cells.  To 
constitutively co-express other variants of the 
hM3 receptor in the inducible 
cell lines, these were transfected with the 
appropriate cDNA construct as described above, 
and resistant clones selected using 1 mg/ml 
G418. All stable cell lines were initially screened 
by fluorescent microscopy for receptor 
expression and subsequent specific binding of 
[3H]QNB in cell membranes.  
 
Cell membrane preparation 
Pellets of cells were frozen at -80oC for a 
minimum of 1 hour, thawed and resuspended in 
ice-cold 10 mM Tris, 0.1 mM EDTA, pH 7.4 
(TE buffer) supplemented with Complete 
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protease inhibitors cocktail (Roche Diagnostics, 
Mannheim, Germany). Cells were homogenized 
on ice by 40 strokes of a glass on Teflon 
homogenizer followed by centrifugation at 1000 
x g for 5 min at 4°C to remove unbroken cells 
and nuclei. The supernatant fraction was 
removed and passed through a 25-gauge needle 
10 times before being transferred to 
ultracentrifuge tubes and subjected to 
centrifugation at 50,000 x g for 45 min at 4°C. 
The resulting pellets were resuspended in ice-
cold TE buffer. Protein concentration was 
assessed and membranes were stored at -80°C 
until required. 
 
Radioligand binding assays 
Saturation binding curves were initiated by the 
addition of 1g (hM3WT) or 5 g (hM3 RASSL) 
of membrane protein to assay buffer (20 mM 
HEPES, 100 mM NaCl, and 10 mM MgCl2, pH 
7.4) containing varying concentrations of 
[3H]QNB (50.5 Ci/mmol). Non-specific binding 
was determined in the presence of 10 µM 
atropine. Reactions were incubated for 90 min at 
25oC, and bound ligand was separated from free 
by vacuum filtration through GF/C filters 
(Brandel Inc., Gaithersburg, MD, USA). The 
filters were washed twice with assay buffer, and 
bound ligand was estimated by liquid 
scintillation spectrometry. 
 
Cell lysates and Western blotting 
Cells were washed once in cold PBS and 
harvested with ice-cold RIPA buffer (50 mM 
HEPES, 150 mM NaCl, 1% Triton X-100, and 
0.5% sodium deoxycholate, 10 mM NaF, 5 mM 
EDTA, 10 mM NaH2PO4, 5% ethylene glycol, 
pH 7.4) supplemented with Complete protease 
inhibitors cocktail (Roche Diagnostics, 
Mannheim, Germany). Extracts were passed 
though a 25-gauge needle and incubated for 15 
min at 4oC while spinning on a rotating wheel. 
Cellular extracts were then centrifuged for 
30 min at 14000 x g and the supernatant was 
recovered. Samples were heated at 65oC for 15 
min and subjected to SDS-PAGE analysis using 
4–12% BisTris gels (NuPAGE, Invitrogen) and 
MOPS buffer. Proteins were then 
electrophoretically transferred onto nitrocellulose 
membranes that were blocked for 45 min in 5 % 
fat-free milk in TBST (1 x TBS containing 0.1 % 
(v/v) Tween 20) and subsequently incubated with 
the required primary antibody overnight at 4oC. 
Incubation with the appropriated horseradish 
peroxidase-linked IgG secondary antiserum was 
performed for 2 hrs at room temperature. 
Immunoblots were developed by application of 
enhanced chemiluminescence solution (Pierce 
Chemical, Rockford, IL USA). 
 
[Ca2+]i mobilization assays 
Cells expressing receptor constructs were grown 
in clear-bottom black 96 well plates (Greiner 
Bio-One Ltd, Stonehouse, UK) and for the 
required length of time. Cells were incubated at 
37oC in the dark with the Ca2+ sensitive dye 
Fura-2 diluted to 3 µM in DMEM for 30 
minutes. Cells were washed twice with HEPES 
physiological saline solution (130 mM NaCl, 5 
mM KCl, 1 mM CaCl , 1 mM MgCl , 20 mM 
HEPES, and 10 mM D-glucose, pH 7.4) and 
transferred to a
2 2
 FlexStation II (Molecular 
Devices, Sunnydale CA) where they were 
stimulated with different drugs and mobilization 
of intracellular calcium was recorded as changes 
of Fura-2 340/380 nm ratio. 
 
Immunocytochemistry 
Cells grown on poly-D-lysine-coated coverslips 
(number 0) were rinsed twice with PBS and cell 
nuclei were stained by incubating cells for 
15 min at 37 °C with fresh PBS containing 
10 μg/ml of the nuclear DNA-binding dye 
Hoechst 33342 (Invitrogen). Samples were then 
washed 3–4 times with PBS, fixed in a 4% 
paraformaldehyde/PBS solution for 10 min and 
washed three times with ice-cold PBS prior to 
the blocking step performed with 3% (w/v) non-
fat dried skimmed milk powder in PBS (non-
permeabilized cells) or 3% (w/v) non-fat dried 
skimmed milk powder plus 0.15% Triton X100 
in PBS (permeabilized cells) for 10 min at room 
temperature. Cells were incubated with the 
appropriate primary antibody dilution for 1 h 
(22°C) and subsequently washed twice with 
PBS. Cells were then incubated for a further 1 h 
with a dilution of secondary antibody at room 
temperature. After washing with PBS, coverslips 
were mounted on to glass slides and viewed 
using an epifluorescence microscope.  
 
Epifluorescence imaging of SNAP-tag proteins 
in live cells 
Cells stably expressing the receptor of interest 
were grown on coverslips pre-treated with 0.1 
mg/ml poly-D-lysine. SNAP-tag specific 
substrates were diluted in complete DMEM 
medium from a stock solution yielding a 
labelling solution of 5 µM dye substrate. The 
medium on the cells expressing a SNAP-tag 
fusion protein was replaced with the labelling 
solution and incubated at 37°C, 5% CO2 for 30 
minutes. Cells were washed three times with 
complete medium and a further time with 
Regulation of muscarinic receptor oligomerization 
 
 5
HEPES physiological saline solution (130 mM 
NaCl, 5 mM KCl, 1 mM CaCl , 1 mM MgCl , 
20 mM HEPES, and 10 mM D-glucose, pH 7.4). 
Coverslips were then transferred to a microscope 
chamber where they were imaged using 
2 2
an 
inverted Nikon TE2000-E microscope (Nikon 
Instruments, Melville, NY) equipped with a 40x 
(numerical aperture-1.3) oil-immersion Pan 
Fluor lens and a cooled digital photometrics Cool 
Snap-HQ charge-coupled device camera (Roper 
Scientific, Trenton, NJ). For internalization 
studies, ligands were added to the microscope 
chamber and fluorescent images were acquired at 
different time intervals for 40 minutes. 
 
Homogeneous time-resolved FRET studies 
Cells expressing the receptors of interest were 
grown to100000 cells per well in solid black 96 
well plates (Greiner Bio-One) pre-treated with 
0.1 mg/ml poly-D-lysine. The growth medium 
was replaced with 100 µl of a mix containing the 
fixed optimal concentrations of donor and 
acceptor, Tag-lite SNAP-Lumi4-Tb and Tag-lite 
SNAP-Red (Cisbio Bioassays, Bagnols-sur-
Cèze, France). Plates were incubated for 1 h at 
37°C, 5% CO2 in a humidified atmosphere, and 
subsequently washed four times in labelling 
medium (Cisbio Bioassays). Plates were either 
read directly after this or further processed to test 
the effect of receptor ligands. For the later 
experiment, several drug concentrations were 
added to the plates after being washed in 
labelling medium; they were then incubated at 
set temperatures and time and read out on a 
PheraStar FS (BMG Labtechnologies, 
Offenburg, Germany) HTRF compatible reader. 
Both the emission signal from the Tag-lite 
SNAP-Lumi4-Tb cryptate (620 nm) and the 
FRET signal resulting from the acceptor Tag-lite 
SNAP-Red (665 nm) were recorded. Finally, the 
specific fluorescent signal was calculated by 
subtracting from the total 665 nm signal that 
obtained from cells labelled but not expressing 
the receptor (un-induced cells), and calculating 
the 665/620 ratio.  
 
Live cell epifluorescence intermolecular 
Cerulean-Citrine FRET microscopy 
Cells were grown on poly-D-lysine treated glass 
coverslips (number 0) and induced with 
doxycycline to express the appropriate Cerulean- 
and Citrine-tagged receptor fusion proteins and 
tandem positive control constructs. Cells were 
placed into a microscope chamber containing 
physiological HEPES-buffered saline solution 
(130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 20 mM HEPES, and 10mM D-glucose, 
pH 7.4). Cells were then imaged using an 
inverted Nikon TE2000-E microscope (Nikon 
Instruments) equipped with a 40 x (numerical 
aperture = 1.3) oil immersion Fluor lens and a 
cooled digital photometrics CoolSnap-HQ, 
(Roper Scientific, Trenton, NJ), attached to the 
left hand microscope port or a CoolSnap-HQ2 
connected to the bottom port. Excitation light 
was generated from a computer-controlled 
Optoscan monochromator (Cairn Research, 
Faversham, Kent, UK) which was coupled to an 
ultra-highpoint intensity 75 W xenon arc 
Optosource lamp (Cairn Research). 
Monochromator was set to 430 and 500 nm for 
the sequential excitation of Cerulean- and 
Citrine-tagged receptors or fused and non-fused 
Cerulean and Citrine respectively. Excitation 
light was reflected through the Fluor objective 
lens using a CFP/YFP dual band dichroic 
(Semrock; Rochester, NY, Cat No-: FF440/520-
Di01). Using the multiple dimensional 
wavelength acquisition module of MetaMorph, 
acceptor, FRET and donor channel images were 
acquired using the same exposure time, (175 
msec or 250 msec), and were detected using 
either a high-speed emission filterwheel (Prior 
Scientific Instruments, Cambridge, UK) coupled 
to a 12 bit mode Cool Snap-HQ digital camera, 
(left hand port), or a Quadview 2, (QV2), image 
splitting device attached to a Cool Snap-HQ2 
camera operated in 14-bit mode, (bottom port). 
Using the emission filter wheel configuration, 
acceptor, FRET and donor signals were 
sequentially detected using 542/27 nm and 
472/30 nm emitters supplied by Semrock. 
Detection of equivalent signals using the QV2 
image splitter was achieved using the following 
Chroma, (Chroma, Brattleboro, VT), ET series 
dichroic and emitters: ET t505LPXR dichroic, 
ET535/30m, ET 470/30m. The image splitting 
device had the advantage that the FRET and 
donor signals could be acquired simultaneously 
without any potential threat of motion. Exposure 
time, binning, (2 x 2), and camera gain were kept 
constant for all acquisitions taken during each 
experiment. Computer control of all electronic 
hardware and camera acquisition was achieved 
using Metamorph software (version 7.6.3 
Molecular Devices, Sunnydale, CA).  
 
FRET signal correction and normalization of 
the FRET signal to donor and acceptor FP 
expression levels  
Saved acceptor, FRET and donor channel images 
were background subtracted and net corrected 
FRET values from raw FRET images were 
corrected using Youvan’s fully specified 
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bleedthrough algorithm (36): Net corrected 
FRET=Raw FRET-[Acceptor-(DA x Donor)] x 
[AF]-[Donor-(AD x Acceptor)] x [DF], where 
DA and AD represent the proportion of donor or 
acceptor bleedthrough, (BT) into the acceptor 
and donor channel respectively. AF and DF 
represent the amount of acceptor and donor 
contamination in the raw FRET signal channel. 
All BT coefficients were calculated from control 
cells expressing Cerulean or Citrine alone. 
Net corrected FRET values were ratiometrically 
normalized to the amount of donor and acceptor 
FP expressed to generate a final ratiometric 
value, (RFRET) which was dependent on protein 
expression levels. For this purpose, the equation 
RFRET=Raw FRET/[Acceptor-(DA x Donor)] x 
[AF] + [Donor-(AD x Acceptor)] x [DF] was 
used. Knowing the expected bleedthrough of the 
donor and acceptor into the FRET channel; 
therefore in the absence of energy transfer, 
RFRET will have a predicted value of 1. Values 
greater than 1 reflect the occurrence of FRET. 
Quantified RFRET values provided markedly 
better data quality compared to other ratiometric 
FRET metric algorithms (37). 
 
RESULTS 
 
The human M3 muscarinic acetylcholine 
receptor was modified at the N-terminus to 
incorporate the Flag-epitope tag and at the C-
terminus via in-frame fusion of the modified 
yellow fluorescent protein Citrine.  This 
generated the Flag-hM3WT-Citrine construct.  
Incorporation of Tyr 149 Cys (position 3.33) and 
Ala 239 Gly (position 5.46) mutations has been 
reported to generate a form of the M3 muscarinic 
receptor with substantially reduced potency for 
the endogenous agonist acetylcholine but which 
is able to bind and respond to the synthetic 
ligand clozapine-N-oxide (25).  This form of the 
M3 muscarinic receptor was modified at the N-
terminus to incorporate the c-myc epitope tag 
and at the C-terminus via in-frame fusion of the 
modified cyan fluorescent protein Cerulean. This 
generated the myc-hM3RASSL-Cerulean 
construct.  Each of these constructs was inserted 
into the Flp-In locus of Flp-InTM T-RExTM 293 
cells and pools of positive cells selected. No 
visible expression of either construct was 
observed in the absence of the antibiotic 
doxycycline (Figure 1A, 1B). However, 
sustained addition of doxycyline resulted in 
expression of each form as monitored by 
fluorescence corresponding to the Citrine- and 
Cerulean-fluorescent proteins respectively 
(Figure 1A, 1B). Imaging of such cells 
suggested that the bulk of each construct was 
located at the plasma membrane (Figure 1A, 
1B). In functional studies measuring ligand-
induced elevation of [Ca2+]i cells harboring Flag-
hM3WT-Citrine at the Flp-In locus, but in which 
expression of the receptor construct had not been 
induced, clozapine-N-oxide was without effect at 
concentrations up to 1 x 10-4M.  This was 
unaltered by treatment with doxycycline (up to 1 
g.ml-1, 24h) to induce receptor expression 
(Figure 1C). By contrast, a weak response to 
carbachol could be recorded in untreated cells, 
with estimated EC50 > 1 x 10-4M. This may 
reflect either low levels of endogenous 
expression of the M3 muscarinic receptor, as has 
been reported previously in HEK293 cells (38), 
or low level expression of the construct in the 
absence of doxycycline.  Following induction of 
Flag-hM3WT-Citrine a robust response to 
carbachol was observed with EC50 4.0 +/- 0.8 x 
10-7M (mean +/- SEM, n = 4) (Figure 1C). As 
anticipated, both in the absence and presence of 
doxycycline, Flp-InTM T-RexTM cells harboring 
myc-hM3RASSL-Cerulean displayed no 
response to carbachol at concentrations up to 1 x 
10-4M (Figure 1D). A very weak response to 
clozapine-N-oxide was observed in these cells in 
the absence of doxycycline (Figure 1D). 
However, a robust response to clozapine-N-oxide 
with EC50 = 1.5 +/- 0.3 x 10-8M (mean +/- SEM, 
n = 3) developed following induction of myc-
hM3RASSL-Cerulean by treatment with 
doxycycline (Figure 1D). Saturation [3H]QNB 
binding studies demonstrated that Flag-hM3WT-
Citrine bound this ligand with Kd = 68 +/- 33 pM  
(mean +/- SEM, n = 4), similar to values reported 
for the unmodified receptor.  myc-hM3RASSL-
Cerulean had almost 40 fold lower affinity (Kd = 
2.64 +/- 0.24 nM, mean +/- SEM, n = 4) for this 
ligand.  To assess if this reduction in affinity for 
[3H]QNB was also noted for other muscarinic 
antagonists, the affinity of atropine as a 
competitive antagonist at both Flag-hM3WT-
Citrine and myc-hM3RASSL-Cerulean was 
assessed by Schild analysis.  Herein, the ability 
of a range of concentrations of atropine to shift 
concentration-response curves to carbachol or 
clozapine-N-oxide respectively was measured. 
Analysis of such studies produced estimates of 
affinity for atropine of 3.3 x 10-9M for the wild 
type receptor and 9.5 x 10-9M for the RASSL, 
confirming the somewhat lower affinity of 
atropine for the RAASL mutant that had been 
described previously (17). 
Cells harboring myc-hM3RASSL-Cerulean at 
the Flp-In locus were subsequently further 
transfected with Flag-hM3WT-Citrine. Clones 
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cell surf
lag-hM WT-
nal structure of the oligomeric 
complex
expressing this construct constitutively and 
stably were then isolated. Flag-hM3WT-Citrine 
was predominantly present at the plasma 
membrane (Figure 2A), whereas, treatment with 
doxycycline was required for turn-on of 
expression of myc-hM3RASSL-Cerulean in 
these cells (Figure 2A). Induction of expression 
of myc-hM3RASSL-Cerulean was time-
dependent, reaching maximal levels within 24h 
(Figure 2B). This, however, had little effect on 
the expression level of Flag-hM3WT-Citrine 
(Figure 2B). As anticipated, based on the 
pharmacological characteristics of cells able to 
express each variant individually, in these cells 
carbachol was an effective and potent agonist in 
both the absence (EC50 = 2.4 +/- 1.3 x 10-8M, 
mean +/- SEM, n = 3) and presence (EC50 = 3.7 
+/- 0.14 x 10-8M,  mean +/- SEM, n = 3) of 
doxycycline (Figure 2C). By contrast, 
clozapine-N-oxide was more than 650 fold more 
potent (EC50 = 5.5 +/- 0.8 x 10-8M, mean +/- 
SEM, n = 3) following treatment with 
doxycycline (Figure 2C).  Merging of images of 
the location of Flag-hM3WT-Citrine and myc-
hM3RASSL-Cerulean in cells induced to express 
the RASSL construct indicated almost perfect 
overlap of localization of the two forms at the
ace (Figure 2D). 
 Such ‘co-localization’ studies can only 
define proximity within a distance of some 300 
nm due to the current limits of light microscopy.  
To explore potential direct interactions between 
these two forms of the hM3 receptor FRET 
imaging studies (Figure 3) were performed and 
both corrected and ratiometric FRET values 
calculated (Figure 3A, B). Both of these 
calculations indicated that the visual overlap of 
distribution of the two hM3 receptor variants was 
consistent with the formation of F 3
Citrine-myc-hM3RASSL-Cerulean 
dimers/oligomers.  The ability of differing 
concentrations of doxycycline to induce varying 
amounts of the FRET energy donor myc-
hM3RASSL-Cerulean was assessed by each of 
cell imaging (Figure 3A), direct measures of 
fluorescence intensity corresponding to the 
Cerulean fluorescent protein (Figure 3C) and 
anti-c-myc immunoblotting studies (Figure 3D).  
Maintained levels of Flag-hM3WT-Citrine in 
these cells were similarly confirmed by each of 
cell imaging (Figure 3A), assessing fluorescence 
intensity corresponding to the Citrine fluorescent 
protein (Figure 3C) and anti-Flag 
immunoblotting (Figure 3D). Both corrected 
FRET and ratiometric FRET were then 
calculated at varying acceptor to donor ratios in 
these cells. These initially increased, from a lack 
of measurable signal in the absence of donor to 
reach a peak after exposure to 100 ng.ml-1 
doxycycline, after which FRET signals were 
reduced with turn-on of higher levels of myc-
hM3RASSL-Cerulean (Figure 3B). Interestingly, 
addition of carbachol (1 x 10-3M), but neither 
clozapine-N-oxide (1 x 10-4M) nor atropine (1 x 
10-5M), reduced substantially the calculated 
ratiometric FRET signals (Figure 3E). This is 
consistent with carbachol altering the 
organizatio
. 
FRET between pairs of fluorescent 
proteins linked to polypeptides of interest is a 
well characterized means to observe protein-
protein interactions in living cells (28-29). 
However, a novel form of homogenous time-
resolved FRET (htrFRET), based on SNAP-
tagging, and marketed as TagLiteTM (32), has 
recently been introduced. This is suitable to 
monitor cell surface protein-protein interactions 
without the need for antibodies that, because of 
their potential to induce clustering, have been 
suggested to limit interpretation of more 
traditional time-resolved FRET techniques (28). 
We generated a generic plasmid to allow 
expression of constructs containing an N-
terminal leader sequence, derived from the 
metabotropic glutamate 5 receptor, linked in-
frame to the VSV-G epitope tag sequence, the 20 
kDa SNAP tag (31) and then the receptor of 
interest.  Both the wild type and the RASSL 
forms of the hM3 receptor were cloned into this 
plasmid and these were used to generate lines 
able to express, in an inducible fashion, VSV-G-
SNAP-hM3WT or VSV-G-SNAP-hM3RASSL 
(Figure 4A). Addition of an anti-SNAP-Alexa-
594 labelled antibody to non-permeabilized cells 
identified, in both cases, cell surface receptors 
following induction (Figure 4A). Furthermore, 
addition of the cell-permeant SNAP-505 
substrate, which links covalently to the SNAP 
tag, allowed detection of a small pool of 
intracellular receptors as well as confirming the 
extensive population of cell surface receptors 
(Figure 4A). Merging of images derived from 
cells labelled with either the anti-SNAP antibody 
or SNAP-505 confirmed both cell surface and 
intracellular pools of the hM3 receptor variants 
(Figure 4A). Importantly, the presence of the N-
terminal leader and SNAP tag did not alter basic 
pharmacological characteristics of the receptors. 
Saturation [3H]QNB binding studies indicated a 
Kd of 54 +/- 5 pM (mean +/- SEM, n = 6) for 
VSV-G-SNAP-hM3WT and 2.44 +/- 0.16 nM 
(mean +/ - SEM, n = 4) for VSV-G-SNAP-
hM3RASSL.  Addition of carbachol (1 x 10-3M) 
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roduce significant 
internal
achol nor 
atropine had any effect (Figure 7B).  
 
DISCUSSION 
s can also 
be trans
resulted in internalization of 17.9 +/- 1.2 % of 
cell surface VSV-G-SNAP-hM3WT over a 40 
min period whilst clozapine-N-oxide (1 x 10-4M) 
produced loss of 17.6 +/- 3.54 % of VSV-G-
SNAP-hM3RASSL over the same time period 
(Figure 4B). By contrast, treatment of either cell 
line with the agonist selective for the other 
receptor variant did not p
ization (Figure 4B).   
To establish optimal conditions for the 
Tag-LiteTM htrFRET studies, cells induced to 
express either VSV-G-SNAP-hM3WT or VSV-
G-SNAP-hM3RASSL were incubated with the 
terbium-cryptate energy donor SNAP-Lumi4-Tb. 
The extent of labelling with this reagent was 
dependent on the level of receptor expression 
because treatment of cells with concentrations of 
doxycyline between 0-10 ng.ml-1 increased the 
binding of a range of concentrations of this label 
(5-30 x 10-9M) in an essentially linear fashion 
(Figure 5A and not shown).  Optimization of 
htrFRET signals corresponding to cell surface 
hM3 dimers/oligomers was achieved by varying 
the added concentration of the corresponding 
energy acceptor, SNAP-Red, in the presence of a 
fixed concentration of SNAP Lumi4-Tb (Figure 
5A, 5B).  For both the VSV-G-SNAP-hM3WT 
and VSV-G-SNAP-hM3RASSL cell lines 
(Figure 5B) this was approximately 8 x 10-8M 
(Figure 5A, 5B) and essentially unaffected by 
the level of receptor expression (Figure 5A). 
htrFRET signals were then monitored in cells 
induced to express VSV-G-SNAP-hM3WT after 
addition of a combination of SNAP Lumi4-Tb 
and SNAP-Red. Basal signal, consistent with the 
presence of constitutive cell surface hM3  
receptor dimers/oligomers, remained stable over 
a period of at least 40 min (Figure 6A) and was 
unaffected by the presence of atropine (Figure 
6A). Interestingly, however, the htrFRET signal 
was increased substantially by the addition of 
carbachol (1 x 10-3M). This effect was time-
dependent (Figure 6A), reaching a maximal 
level by 20 min before subsequently declining. 
The extent of the effect of carbachol was 
dependent on the level of receptor expression; 
with lower levels of doxycycline associated with 
a greater effect of carbachol (Figure 6B).  This 
reflected that at higher receptor expression levels 
the basal htrFRET signal was higher than at 
lower expression levels (Figure 6B) and in this 
situation carbachol produced a more limited 
effect on the htrFRET signal (Figure 6B).  The 
effect of carbachol on the htrFRET signal 
corresponding to cell surface VSV-G-SNAP-
hM3WT dimers/oligomers was selective. 
Clozapine-N-oxide was without effect on the 
htrFRET signal (Figure 6A) and whilst atropine 
(1 x 10-5M) produced a small reduction in the 
basal htrFRET signal in some experiments 
(Figure 6A) this was not observed consistently. 
The effect of carbachol was concentration-
dependent with EC50 = 3.3  +/- 1.1 x 10-4M 
(mean +/- SEM, n = 3) (Figure 6C). Studies in 
which carbachol was allowed to compete with 
[3H]QNB to bind to VSV-G-SNAP-hM3WT in 
membranes of cells induced to express this 
construct showed that this potency corresponded 
to the lower of two affinity states for carbachol 
(Figure 6D). Acetylcholine, the endogenous 
agonist of the M3 muscarinic receptor, was also 
able to increase the htrFRET signal as 
extensively as carbachol in cells expressing 
VSV-G-SNAP-hM3WT and was some 60 fold 
more potent than carbachol in so doing (EC50 = 
5.8 x 10-6M) (Figure 6E). Interestingly, in cells 
induced to express VSV-G-SNAP-hM3RASSL, 
clozapine-N-oxide increased the basal htrFRET 
signal in a concentration-dependent fashion 
(Figure 7A) whereas neither carb
 
It is now well established that many, and 
perhaps all, rhodopsin-like, family A GPCRs can 
form dimers and/or higher oligomers (4-7). 
However, the significance of this remains 
uncertain because it is not inherently required to 
allow interaction with a G protein (1-3).  Indeed, 
there is evidence that monomeric family A 
GPCRs may actually mediate G protein-
dependent signals more effectively than dimers 
(2). Signals from GPCRs may also be generated 
in G protein-independent fashion (39), but it 
remains to be established if such signal
duced by monomeric GPCRs.  
A further topic that has attracted 
considerable attention is the question of whether 
ligands modulate the quaternary organization of 
GPCRs. Published data on this topic are highly 
variable (5-8). Given that interactions between 
individual protomers of class A receptor 
dimers/oligomers are not generally based on 
covalent interactions (4-5) then there is clear 
potential for monomer-multimer equilibria to be 
altered by the binding of receptor ligands.  This 
reflects that agonist binding must alter receptor 
conformation (40) to induce states of the receptor 
able to interact more effectively with G proteins 
and other GPCR-interacting proteins. Although 
many studies have suggested that ligand binding 
to receptors does not produce substantial effects 
on GPCR quaternary structure (4-7), a 
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cing and 
reducin
ined directly for each 
compou
considerable number of observations of ligand 
modulation of GPCR dimers/oligomers exist in 
the literature. These include effects of an 
antagonist/inverse agonist drug to promote the 
production of a high affinity dimeric state of the 
M1 muscarinic receptor from receptor monomers 
(25) and the concept that the 2-adrenoceptor 
exists predominantly in a basal tetrameric state 
that is unaffected  by either agonist or antagonist 
ligands whilst  inverse agonists enhance tighter 
packing of the protomers and/or the formation of 
more complex oligomers by reducing 
conformational fluctuations in individual 
protomers (41). Other studies are consistent with 
agonist ligands promoting conformational 
alterations in pre-existing GPCR 
dimers/oligomers (40) and both enhan
g dimerization (4-7, 25, 42-44). 
It is clearly possible that such variation 
reflects intrinsic differences in the organization 
and affinity between protomers of different 
GPCRs. For example, fluorescence recovery 
after photobleaching microscopy has been 
applied to conclude that the 2-adrenoceptor 
forms stable complexes whilst the 1-
adrenoceptor displays only transient interactions 
(45). However, given the range of approaches 
used to detect interactions between GPCRs and 
potential regulation by ligands, it is also possible 
that different techniques might be more or less 
well suited. Resonance energy-based approaches 
have dominated the field in recent years (27-29, 
46) and studies have generally added energy 
acceptor and donor moieties to the intracellular 
C-terminal tail of the GPCR(s) being studied. 
Strengths and weaknesses of this have been 
reviewed (28) and debated (47-48). One of the 
recent additions to the armorium of approaches is 
a htrFRET method that takes advantage of the 
capacity of small proteins based on mammalian 
O6-alkylguanine-DNA-alkyltransferase to be 
covalently modified with FRET-competent 
energy donor and acceptors (31).  Via addition of 
such a SNAP tag to the extracellular N-terminus 
of class C GPCRs Maurel et al., (32)  were able 
to confirm the presence of cell surface dimers of 
metabotropic glutamate receptor subtypes. They 
also used this approach to provide some 
preliminary data on dimerization of class A 
receptors (32). Herein, we have extended this to 
explore the presence and regulation of 
dimeric/oligomeric complexes at the surface of 
cells stably expressing forms of the M3 
muscarinic acetylcholine receptor and compared 
the results with those obtained via more 
conventional FRET-imaging based studies. A 
key feature of the FRET imaging studies was to 
employ the inducible expression of DNA located 
at the Flp-InTM locus of Flp-InTM T-RExTM 293 
cells (33-35).  This allowed us to regulate 
expression of one form of the M3 muscarinic 
receptor in the presence of an unaltered amount 
of a second form in the same cells, rather than 
attempting to control relative expression levels in 
a substantial series of transient co-transfection 
studies. Transient transfection into heterologous 
cell lines of GPCRs in general and, in particular, 
of the type of highly modified forms used for 
resonance energy transfer studies, often results in 
incomplete folding and their retention in the ER 
and Golgi.  This is a major issue in efforts to 
explore dimerization in so-called ‘saturation’ 
resonance energy transfer studies (28).  These 
require a series of measurements in cells 
expressing differing ratios of energy-donor and 
energy-acceptor species. Therefore, the linkage 
of the energy donor and acceptor species to the 
C-terminal tail of the GPCRs in question results 
in signal being recorded from intracellular 
locations as well as the cell surface.  A second 
key feature of the current studies was the 
combined use of wild type and RASSL forms of 
the M3 muscarinic receptor to take advantage of 
selective agonist pharmacology. One minor 
limitation of the M3 muscarinic receptor RASSL 
is that it binds conventional antagonist ligands 
less well than the wild type receptor. This 
increased the concentration of [3H]QNB needed 
in the ligand binding studies that were used to 
define expression levels and receptor 
pharmacology.  However, with good practise the 
pharmacological characteristics of this variant 
can be fully defined. This is important because 
although the affinity of [3H]QNB was 40 fold 
lower for the RASSL forms of the receptor 
compared to the wild type, variation in affinity 
for the widely used muscarinic receptor 
antagonist atropine was only 3 fold.  Variation in 
ligand affinity at the modified receptor is 
defined, therefore, by the identity of the specific 
ligand and must be determ
nd being studied. 
Both wild type and RASSL forms of the 
M3 muscarinic receptor suitable for FRET 
imaging were expressed predominantly at the 
cell surface of Flp-InTM T-RExTM 293 cells when 
they were induced. Furthermore, strong FRET 
signals between these froms at the cell surface 
membrane were obtained in cells engineered to 
allow their co-expression. However, it should be 
noted that increasing FRET donor amounts in the 
presence of a fixed level of FRET acceptor 
resulted in a bell-shaped curve of ratiometric 
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ertain class A GPCRs, including muscarinic 
 
FRET signal. This is not surprising.  Higher 
levels of donor would be expected to result in a 
greater proportion of non FRET-productive 
donor-donor interactions that are anticipated to 
eventually limit or out-compete productive 
donor-acceptor interactions. In these studies 
carbachol caused a substantial reduction in 
ratiometric FRET signal.  This is consistent with 
either alteration in the organizational structure of 
preformed WT-RASSL M3 receptor complexes 
or the dissociation of such complexes. By 
contrast, the antagonist atropine did not modulate 
such signals substantially. Intra-molecular GPCR 
FRET sensors, constructed in a single GPCR 
protomer, are often used to detect agonist-
induced alterations in FRET signal 
corresponding to relative movements of the 
intracellular ends of transmembrane helices that 
are believed to promote interaction with a G 
protein (49-51). Furthermore, relative re-
orientation of the transmembrane helices that are 
believed to be contact interfaces within GPCR 
dimers/oligomers have been detected upon 
addition of agonist by a number of means (41, 
52-53). However, in many studies employing 
FRET or BRET, limited overall effects of GPCR 
ligands have been noted and interpreted to 
indicate that GPCR dimers/oligomers are present 
constitutively and not regulated acutely (5, 21, 
54).  Surprisingly, unlike carbachol, clozapine N-
oxide did not alter FRET signal in cells induced 
to co-express the hM3 receptor variants. Given 
that FRET signals in these cells must reflect 
complexes containing at least one wild type and 
one RASSL mutant M3 receptor it might have 
been anticipated that agonist occupancy of either 
type of protomer would result in equivalent 
effects on aspects of complex re-organization. 
This reflects that there should be reciprocity in 
regulation between components of a protein 
complex (55).  We do not have a clear 
explanation for why this was not observed. A 
number of possibilities exist. For example, 
although clozapine N-oxide acted as an apparent 
full agonist at the RASSL variant in the Ca2+ 
mobilization studies, it may, because of issues of 
receptor reserve, not truly have the same efficacy 
as carbachol at the wild type receptor. However, 
it was as effective at causing internalization of 
the RASSL variant from the surface of the cells 
as was carbachol in promoting internalization of 
the wild type receptor. Equally, it may be that the 
cell surface complex detected by these studies is 
not a simple 1:1 wild type/RASSL dimer. 
Indeed, there is growing evidence that at least 
receptors, can exist as higher-order complexes 
containing at least 4 protomers (41, 52-53, 56).   
c
  In contrast to the FRET imaging 
studies, those based on the Tag-liteTM system 
produced evidence consistent with either 
significant agonist-induced re-organization 
within constitutive M3 receptor quaternary 
structure or, perhaps more interestingly, agonist-
induced enhancement of 
dimerization/oligomerization. Firstly, these 
effects were produced only by pharmacologically 
appropriate agonists, i.e. carbachol and 
acetylcholine at the wild type receptor and 
clozapine-N-oxide at the RASSL variant. 
Moreover, agonist potencies in these studies 
were consistent with receptor occupancy. 
However, as with the FRET imaging studies, 
clozapine-N-oxide was less effective at the 
RASSL variant than either carbachol or 
acetylcholine at the wild type receptor complex.  
Secondly, effects of carbachol were most 
pronounced at lower levels of receptor 
expression. This is at least consistent with the 
concept that the M3 receptor displays a greater 
propensity to form oligomeric structure at higher 
density. In such a situation agonist might not be 
able to promote this further, whilst at lower 
receptor density there is less quaternary 
organization but this is promoted by agonist 
binding.  One further curiosity of these 
observations was the time-dependence of the 
effects.  These were much slower than the 
anticipated association constant for the ligand.  
Interestingly, FRET studies on purified 2-
adrenoceptors have also shown slow time-
dependent effects of ligands on intra-molecular 
movement between transmembrane helices (57) 
but this is assumed to reflect the artificial 
environment needed to perform the studies. By 
contrast, intact cell intra-(50) and inter-(58) 
molecular FRET studies on the movement of 
receptor helices are much more consistent with 
time courses of physiological function.  
These results have major implications 
for our understanding of ligand regulation of 
GPCR quaternary structure and it will be of great 
interest to see if similar observations are seen 
when studying other closely and less closely 
related GPCRs, both in terms of homo- and 
hetero-meric pairings. They also indicate that 
conclusions as to the direction of effect of 
ligands on such GPCR complexes may depend 
on the approach used. 
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FIGURE LEGENDS 
 
Figure 1 Generation and pharmacological characterization of Flp-InTM T-RExTM 293 cells able 
to express forms of the wild type or RASSL M3 muscarinic acetylcholine receptor on demand 
Flag-hM3WT-Citrine (1A, 1C) or myc-hM3RASSL-Cerulean (1B, 1D) were inserted into the Flp-In 
locus of Flp-InTM T-RExTM 293 cells and pools of positive cells selected. No visible expression of 
either construct was observed in the absence of the antibiotic doxycycline (1A, 1B, -dox and bright 
field images) but cell surface delivery of both was produced after addition of doxycycline ((1A, 1B, + 
dox). Elevation of [Ca2+]i in response to varying concentrations of either carbachol (Cch) or 
clozapine-N-oxide (CNO) was assessed in both un-induced and doxycycline-treated cells (1C, 1D), 
means +/- SE
 
Figure 2 Generation and characterization of Flp-InTM T-RExTM 293 cells able to express 
inducibly the RASSL M3 muscarinic acetylcholine receptor in the presence of constitutive 
expression of wild type M3 muscarinic acetylcholine receptor  
Cells harboring myc-hM3RASSL-Cerulean at the Flp-In locus as in Figure 1 (blue) were subsequently 
further transfected with Flag-hM3WT-Citrine (yellow) and clones expressing this construct 
constitutively and stably were isolated.  A. shows the inducible nature of the RASSL variant (+ dox 
versus – dox). B. Membranes from these cells were isolated after treating with doxycycline for 
varying periods of time, resolved by SDS-PAGE and immunoblotting with anti c-myc (upper panel), 
anti-Flag (middle panel) or anti-GFP (that identifies both Cerulean FP and Citrine FP) (lower panel). 
(Arrowheads show the position of the 105 kDa molecular mass marker). C. Elevation of [Ca2+]i in 
response to varying concentrations of either carbachol (Cch) or clozapine-N-oxide (CNO) was 
assessed in both RASSL un-induced (- Dox) and doxycycline-treated cells (+ Dox) means +/- SEM, n 
= 4. D. Images of Citrine FP (green), Cerulean FP (red) and merging of these images (merge) from 
doxycycline-induced cells were used to construct correlation analyses of color overlap (right hand 
picture).  
 
Figure 3 FRET analysis of interactions between variants of the human M3 muscarinic 
acetylcholine receptor 
A and B. Co-expression of myc-hM3RASSL-Cerulean (donor) with Flag-hM3WT-Citrine (acceptor) 
resulted in raw and corrected (c) FRET signals. Such images were used to calculated ratiometric FRET 
and how this was modulated by controlling the relative levels of donor to acceptor expression by 
treatment of cells with varying concentrations of doxycycline. C. Levels of acceptor (yellow) and 
donor (blue) were quantitated at the cell membrane. D. Quantitation of ratiometric FRET signals 
(Table) and immunological detection of the acceptor (upper panel) and donor (lower panel) at 
various doxycycline concentrations are displayed (arrowhead indicates the position of the 105 kDa 
molecular mass marker). E. Radiometric FRET at the cell membrane was measured after treatment 
with the ligands carbachol, atropine and CNO subsequent to induction of expression of myc-
hM3RASSL-Cerulean with100 ng.ml-1 of doxycycline. 
 
Figure 4 Generation and characterization of Flp-InTM T-RExTM 293 cells able to express SNAP-
tagged variants of human M3 muscarinic acetylcholine receptor 
A. Flp-InTM T-RExTM 293 cells able to express in an inducible fashion VSV-G-SNAP- hM3WT (left 
hand panels) or VSV-G-SNAP- hM3 RASSL (right hand panels) are shown. Following receptor 
induction these were treated with the cell permeant SNAP substrate SNAP-505 (upper panel and 
green), an anti-SNAP antibody labeled with Alexa 594 (middle panel and red) or such images were 
merged (lower panels). Cell nuclei are shown in blue. B. Cells induced as in A (top, VSV-G-SNAP- 
hM3WT; bottom VSV-G-SNAP- hM3-RASSL were labeled with the non-cell permeable reagent Cell-
Surface-SNAP-488 and treated with carbachol (1 x 10-3M) or clozapine-N-oxide (1 x 10-4M) for 0 or 
40 minutes and then imaged. Arrowheads focus attention on receptor populations that became 
internalized in the presence of ligand. 
 
Figure 5 Establishing Tag-LiteTM htrFRET studies to explore receptor dimerization 
Cells induced to express differing amounts of VSV-G-SNAP-hM3WT by treatment with varying 
concentrations of doxycycline were incubated with a range of concentrations of the Tb2+-cryptate 
energy donor SNAP-Lumi4-Tb and cell surface binding of this ligand determined by fluorescence 
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intensity at 620 nm (A, top). Using 4nM SNAP-Lumi4-Tb varying concentrations of the energy 
acceptor SNAP-Red were added to cells induced with varying concentrations of doxycycline (A, 
bottom) to define optimal ratios of energy donor and acceptor to measure receptor homo-interactions.  
B. The concept of the studies is shown for both VSV-G-SNAP-hM3WT and VSV-G-SNAP- 
hM3RASSL. ‘d2’ is a cisbio trademark for ‘a second generation htrf acceptor characterized by an 
organic motif of approximately 1,000 Da that is highly FRET compatible with Eu3+ and 
Tb+2 cryptates’. 
 
Figure 6 Agonists promote structural re-organization and/or dimerization of the M3 muscarinic 
acetylcholine receptor 
htrFRET studies were conducted in cells induced to express either VSV-G-SNAP- hM3WT or VSV-
G-SNAP-hM3RASSL. A. At VSV-G-SNAP-hM3WT carbachol (1 x 10-3M) but not clozapine-N-oxide 
(1 x 10-4M) produced a significant increase in basal htrFRET signal, reaching a maximum after 20 mi
(A). Atropine (1 x 10-5M) produced a small but significant decrease in the signal in some but not all 
studies. B. The extent of effect of carbachol was dependent on the level of receptor expression, with 
substantially greater effects when VSV-G-SNAP- hM3WT expression was lower. C, D. The effect of 
carbachol was concentration-dependent (C) and corresponded to the lower affinity state for carbachol 
as assessed in competition binding studies employing [3H]QNB (D). E. Acetylcholine (Ach) also 
increased htrFRET signal in a concentration-dependent manner. 
 
Figure 7 Clozapine-N-Oxide promotes structural re-organization and/or enhanced dimerization 
of the RASSL M3 muscarinic acetylcholine receptor 
Clozapine-N-oxide produced a concentration-dependent increase of htrFRET signal in cells induced to 
express VSV-G-SNAP-hM3RASSL after 40 min of treatment, whilst carbachol and atropine were 
without effect. 
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